Navigation Links
ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Date:11/10/2010

e in a class by itself.  We think that this new agent has extraordinary potential in treating previously intractable conditions such as the devastating vasculitis seen in autoimmune diseases."

CCX168 Study Results and ANCA-Associated Vasculitis

In Phase I clinical trials CCX168 was safe and well tolerated, with excellent oral bioavailability and dose-proportional exposure increases in human subjects.  Pharmacokinetic and pharmacodynamic data indicated that 30 to 50 mg of CCX168 given orally twice daily in humans results in greater than 90% C5aR coverage in blood at all times, and this is considered optimal for CCX168 evaluation in Phase II trials in vasculitis.

Supporting the Phase I data are results from a mouse model of anti-neutrophil cytoplasmic autoantibody (ANCA) associated glomerulonephritis (GN).  In this study, human C5aR transgenic mice were employed, and ANCA kidney disease was profoundly inhibited by doses of CCX168 that are very similar to those achieved safely in the human Phase I studies.

CCX168 is a highly potent and very selective compound that specifically targets the receptor for the anaphylotoxin designated C5a, a component of the body's complement system and a potent driver of the inflammatory response associated with ANCA-associated vasculitis and other autoimmune disease. In ANCA disease, auto-antibodies lead to the activation and increased adhesiveness of neutrophils to endothelial cells that line the interior surfaces of blood vessels in the kidney and other organs.  These adhering neutrophils accumulate inside the blood vessels and initiate an inflammatory cascade.  Activation of the complement pathway occurs as a consequence, with production of C5a, one of the most potent pro-inflammatory mediators of the complement system.  C5a, through binding to its receptor C5aR, induces expression of additional adhesion molecules and chemotactic factors, thus
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today ... 2015.  The net loss and the loss from operations ... million, respectively, compared to $10.7 million and $8.8 million ... 31, 2015, Alexza had consolidated cash, cash equivalents, marketable ... "We continue to focus on ways in which to ...
(Date:5/6/2015)... The Parenteral Drug Association (PDA) Board of ... Richard M. Johnson to continue as President ... pleased to have Richard Johnson continue as ... the Chair of the Board of Directors. "Under Richard,s ... has led a strong staff and dedicated volunteers, hosting ...
(Date:5/6/2015)... Del. , May 6, 2015  Rigrodsky & Long, P.A.: ... Aerie Pharmaceuticals, Inc. (NASDAQ GM: AERI )? , Did ... 2015, inclusive? , Did you lose money in your investment ... your rights? Rigrodsky & Long, P.A. ... MacFall , announces that a complaint has been filed in the ...
Breaking Medicine Technology:Alexza Reports 2015 First Quarter Financial Results 2Alexza Reports 2015 First Quarter Financial Results 3Alexza Reports 2015 First Quarter Financial Results 4Alexza Reports 2015 First Quarter Financial Results 5Alexza Reports 2015 First Quarter Financial Results 6Alexza Reports 2015 First Quarter Financial Results 7Alexza Reports 2015 First Quarter Financial Results 8Alexza Reports 2015 First Quarter Financial Results 9Alexza Reports 2015 First Quarter Financial Results 10PDA Extends Richard M. Johnson as President/CEO for Six Additional Years 2SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 3
... SPRING, Md., Oct. 21 The U.S. Food ... information has been added to the label for ... life-threatening side effects on the heart when used ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: ...
... ROCHESTER, N.Y., Oct. 21 VirtualScopics, Inc. (Nasdaq: ... for clinical trials, announced today that before the market ... its third quarter 2010 financial results. The company will ... EST. VirtualScopics, President and Chief Executive ...
Cached Medicine Technology:New Label Changes for Commonly Prescribed HIV Drug Invirase 2VirtualScopics Schedules Third Quarter 2010 Earnings Announcement 2
(Date:5/7/2015)... 2015 When people think about protecting their ... their roofs than their basements. However, heavy rain falls also ... and basements. While flooding is an obvious problem in a ... unfinished areas dry to avoid a musty smell . ... Even small amounts of water can cause foundation damage, mold ...
(Date:5/7/2015)... May 07, 2015 Five CHI ... CHI Health Bergan Mercy, CHI Health Immanuel and ... Midlands in Papillion, Neb.; and CHI Health Mercy ... for achieving high-quality standards of care by the ... dedicated to best practices in cardiovascular care. The ...
(Date:5/6/2015)... May 07, 2015 Device Patent Law Changes:, ... — 11:00 a.m. – 12:30 p.m. EDT, http://www.fdanews.com/DevicePatentLaw ... expensive patent lawsuits and claims that waste their time. ... these cases could be prevented if devicemakers better understand the ... court rulings and revisions to patent laws from all around ...
(Date:5/6/2015)... As the exclusive hospital of the Tampa Bay Buccaneers, Florida ... Raymond James Stadium for all the “Bucs Babies” celebrating their ... into the “Bucs Babies” program last year. , “It ... particularly those born at the Florida Hospitals here in our ... really enjoyed my time participating in the festivities, interacting with ...
(Date:5/6/2015)... CA (PRWEB) May 06, 2015 On ... Celebrities on Plastic Surgery ,” compiled quotes about ... includes Jennifer Aniston, pop singer Iggy Azalea, and Gwyneth ... their sentiments about having plastic surgery themselves; ... about society and its expectations of youth and beauty. ...
Breaking Medicine News(10 mins):Health News:Spring Storms Bring Musty Smell Inside 2Health News:Spring Storms Bring Musty Smell Inside 3Health News:Five CHI Health Facilities in Nebraska, Iowa Recognized for High-Quality Care by Accreditation for Cardiovascular Excellence 2Health News:Five CHI Health Facilities in Nebraska, Iowa Recognized for High-Quality Care by Accreditation for Cardiovascular Excellence 3Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 2Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 3Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 2Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 3Health News:Plastic Surgery: Sixteen Celebrities Offer their Opinion about Going Under the Knife 2
... Holmes,Inc. (Amex: HH ) today announced that it ... before market on Friday, March 14, 2008.,The Company will ... at,11:00am EDT., Conference Call, To participate in ... code: Hooper Holmes. A live web cast will be ...
... Ohio, March 11 An informal,industry group committed ... high quality health care today issued a joint ... the American Association of Preferred,Provider Organizations (AAPPO) and ... group continues to be concerned that H.B. 125, ...
... Bethesda, MD (March 11, 2008) A combined ... survival rates for patients suffering from advanced liver bile ... in Clinical Gastroenterology and Hepatology , the official ... , Researchers in the study found that while stenting ...
... Tenn., March 11 Ambulatory Services of,America, Inc. ... ROSA of,Southern New Jersey, LLC, a joint venture ... subsidiary, Radiation Oncology Services,of America, Inc. ROSA of ... venture, which brings the number of radiation oncology,facilities ...
... Scoliosis Awareness Month in June 2008, STOUGHTON, ... who survived scoliosis surgery to become a,nationally-ranked squash ... for,the National Scoliosis Foundation. The other spokesperson, Sarah ... competitive dancing after recovering,from her scoliosis surgery this ...
... house world class research, center in country,s Indianapolis region, an epicenter ... mainstream ... practice, WHITESTOWN, Ind., ... Indiana Gov. Mitch Daniels, broke,ground today on its $140 million automated pharmacy ...
Cached Medicine News:Health News:Hooper Holmes Announces Fourth Quarter Earnings Release Date and Conference Call Information 2Health News:Health Plan and Preferred Provider Network Communities Issue Joint Statement on Passage of Healthcare Simplification Act 2Health News:Combined stenting and photodynamic therapy improves survival in late stage liver cancer patients 2Health News:Combined stenting and photodynamic therapy improves survival in late stage liver cancer patients 3Health News:Ambulatory Services of America, Inc. Announces Joint Venture with Southern Ocean County Radiation Oncology, LLC 2Health News:Author Elizabeth Golden and Dancer Sarah Patellos to Serve as National Spokespersons for the National Scoliosis Foundation 2Health News:Author Elizabeth Golden and Dancer Sarah Patellos to Serve as National Spokespersons for the National Scoliosis Foundation 3Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 2Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 3Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 4Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 5
Micro Decker Pituitary Rongeurs, 6 length 150 mm, heavy duty....
... skull pin to utilize cutting edges instead of a ... into bone the Hifix pin drills a neat path ... fixation over standard skull pins. The Hifix pin is ... and in the bremer 3D halo crown. Hifix pins ...
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
Mayfield Disposable Adult (plastic) Skull Pins are designed for rigid skeletal fixation....
Medicine Products: